Neogen Co. (NASDAQ:NEOG) Director Jack C. Parnell sold 439 shares of the stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $70.00, for a total value of $30,730.00. Following the sale, the director now owns 5,000 shares of the company’s stock, valued at $350,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
NASDAQ NEOG traded down $0.92 during trading on Monday, reaching $69.37. 2,450 shares of the company traded hands, compared to its average volume of 259,197. Neogen Co. has a 1-year low of $50.60 and a 1-year high of $97.38. The stock has a 50 day moving average price of $63.84. The firm has a market capitalization of $3.63 billion, a P/E ratio of 60.29, a price-to-earnings-growth ratio of 5.78 and a beta of 1.38.
Neogen (NASDAQ:NEOG) last posted its earnings results on Tuesday, July 23rd. The company reported $0.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.28 by $0.02. Neogen had a net margin of 14.53% and a return on equity of 9.86%. The company had revenue of $109.80 million during the quarter, compared to analysts’ expectations of $110.14 million. During the same quarter in the previous year, the company posted $0.33 earnings per share. Neogen’s quarterly revenue was up 1.6% compared to the same quarter last year. On average, equities analysts anticipate that Neogen Co. will post 1.22 earnings per share for the current year.
NEOG has been the subject of several recent research reports. Guggenheim assumed coverage on Neogen in a report on Thursday, May 23rd. They set a “neutral” rating for the company. Craig Hallum raised their target price on Neogen from $72.00 to $78.00 and gave the company an “in-line” rating in a report on Wednesday, July 24th. Zacks Investment Research lowered Neogen from a “hold” rating to a “sell” rating and set a $68.00 price objective on the stock. in a research note on Friday, June 21st. BidaskClub upgraded Neogen from a “buy” rating to a “strong-buy” rating in a research note on Friday. Finally, ValuEngine raised Neogen from a “hold” rating to a “buy” rating in a research report on Thursday. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $73.00.
Neogen Company Profile
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment primarily offers diagnostic test kits and complementary to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells.
Recommended Story: Outstanding Shares
Receive News & Ratings for Neogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neogen and related companies with MarketBeat.com's FREE daily email newsletter.